The recently published American guidelines for the management of dyslipidemia reinforce an important shift in how we understand cardiovascular risk. This is not so much about new targets, but about a more precise way of interpreting what is actually happening in each patient.

For many years, dyslipidemia has been understood as an alteration in numbers: elevated LDL cholesterol implied increased risk, and reducing it was the primary treatment goal. While useful, this approach oversimplifies a much more complex process.

Dr. Carlos Martí – Neolife Medical Team

Cardiovascular Prevention

For a long time, the focus has been on identifying out-of-range values. However, we now know that the atherosclerotic process (the accumulation of fat in the arteries) begins long before these values change or symptoms appear.

This explains why some individuals experience cardiovascular events despite having apparently normal blood tests, while others with elevated levels remain stable for years. The difference lies in what is not always visible in conventional testing: particle number, cumulative burden, or the presence of subclinical disease. Today’s tools allow access to this information and enable a better understanding of where each patient stands in the disease process.

The goal, therefore, is not only to detect abnormalities once they become evident, but to interpret earlier signals that allow for more proactive intervention. In cardiovascular health, it is not just about treating risk when it appears, but about understanding how it develops from much earlier stages.

Beyond Cholesterol: Understanding What We Really Measure

LDL cholesterol has traditionally been the cornerstone of diagnosis and treatment. However, not all LDL particles have the same impact, and a normal value does not guarantee low risk. In this context, apolipoprotein B (ApoB) has gained importance. It is a protein present in all particles capable of forming plaques in the arteries, meaning that measuring it is essentially counting how many “potentially harmful particles” are circulating in the bloodstream.

Unlike LDL, which measures how much cholesterol these particles carry, ApoB indicates how many particles are actually present. This is particularly useful in individuals with overweight, diabetes, or elevated triglycerides, where LDL may appear normal despite high risk.

But not all risk depends on lifestyle or metabolism. There is also a genetic component that may go unnoticed in standard blood tests. This is where lipoprotein(a), or Lp(a), becomes relevant. It is a particle similar to LDL but with unique characteristics that make it especially atherogenic (more likely to promote plaque formation in the arteries). Its levels are largely genetically determined, meaning a person may have elevated Lp(a) from birth without knowing it. As a result, even with apparently normal cholesterol levels, cardiovascular risk may be higher than expected if Lp(a) is elevated. For this reason, current guidelines recommend measuring it at least once in a lifetime.

The integration of these biomarkers provides a more comprehensive assessment of risk, moving beyond a model based solely on total cholesterol or LDL.

From Estimating Risk to Detecting Disease

Another key change reinforced by the new guidelines is the use of imaging techniques to refine risk assessment in selected patients. Coronary artery calcium (CAC) measures the amount of calcium deposited in the arteries of the heart. Its presence indicates that atherosclerosis already exists, even in the absence of symptoms.

Although not yet part of the main guideline recommendations, carotid ultrasound allows direct visualization of the neck arteries and the detection of plaques or arterial wall thickening (intima-media thickness, IMT, a marker of arterial health). While CAC identifies more advanced disease, carotid ultrasound can provide information about earlier stages of the process.

At Neolife, these tools are part of an advanced preventive medicine approach. This allows for more precise adjustment of treatment intensity and prioritization of interventions in patients who might otherwise appear low-risk based on conventional testing.

We combine biomarkers such as ApoB and lipoprotein(a) with imaging techniques, including carotid ultrasound, to obtain a more complete picture of vascular health. The goal is not only to estimate future risk, but to determine whether the disease process has already begun—even in its earliest stages.

A More Precise, Not More Complex Approach

The evolution in dyslipidemia management does not mean performing more tests on every patient, but rather selecting more effectively which information is needed in each case.

In practice, this translates into:

• Knowing when a basic blood test is sufficient
• Identifying when measuring ApoB or lipoprotein(a) is useful
• Considering markers such as high-sensitivity CRP (an indicator of low-grade inflammation), which can increase cardiovascular risk even with normal cholesterol levels
• Using imaging tests to clarify uncertainty about actual risk
• Adjusting treatment based on the patient’s overall profile, not just a single value

This approach allows for the identification of high-risk individuals who might otherwise go unnoticed with conventional testing, while also avoiding unnecessary treatment in those who do not need it.

At Neolife, this strategy has long included the assessment of low-grade inflammation, understood as a key factor in the development of atherosclerosis. It is not only about how much cholesterol circulates, but about the environment in which that cholesterol acts.

Applying a Comprehensive Strategy: Addressing the Cause, Not Just the Numbers

Lifestyle interventions remain the foundation of treatment, but their impact goes far beyond lowering cholesterol. Reducing visceral fat (fat stored around organs), improving insulin sensitivity, engaging in strength training and aerobic exercise, and ensuring adequate sleep all directly influence the formation of atherogenic particles, inflammation, and arterial health.

This explains why two individuals with the same cholesterol levels may have completely different risks. The goal is not just to improve lab results, but to modify the metabolic environment in which the disease develops.

Understanding Risk Before It Becomes Visible

Cardiovascular risk does not appear suddenly—it develops progressively over time. We now know that the atherosclerotic process begins long before laboratory values change or symptoms arise. This is why a conventional blood test does not always reflect true risk. Factors such as particle number, inflammation, and subclinical disease can make a critical difference. The real advancement lies in being able to access this information and understand where each patient stands in the process, allowing for earlier and more effective intervention.

At Neolife, this approach is part of daily clinical practice: integrating advanced laboratory testing, biomarkers, and vascular imaging to detect risk before it becomes clinically apparent and to address it in a personalized way.

Because in cardiovascular health, the goal is not simply to act in time—but to prevent the problem from developing in the first place.

BIBLIOGRAPHY

(1) Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, Blankstein R, Brewer LC, Cho L, de Ferranti SD, Gianos E, Gluckman TJ, Gradney KF, Isiadinso I, Lloyd-Jones DM, Marrs JC, Martin SS, McLain KH, Mehta LS, Mora S, Mulugeta WM, Natarajan P, Navar AM, Orringer CE, Polonsky TS, Reynolds HR, Saseen JJ, Shapiro MD, Soffer DE, Tynes SA, Villavaso CD, Virani SS, Wilkins JT. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026 Mar 13:S0735-1097(25)10254-4. doi: 10.1016/j.jacc.2025.11.016. Epub ahead of print. PMID: 41824590.

(2) Gráfico extraído del blog de https://peterattiamd.com/measuring-cardiovascular-disease-risk-and-the-importance-of-apob-part-1/

Pulse wave velocity (PWV) is now the most accurate tool for the early detection of arterial aging and for understanding when hypertension truly begins—even when office blood pressure values are still within the normal range.

Added to this is the value of the renin/aldosterone ratio, which allows us to identify the underlying mechanism driving blood pressure elevation in each individual and to personalize management with unprecedented precision. This is what hypertension looks like in 2026: true anticipation and treatment tailored to each patient’s physiology.

Dr. Carlos Martí – Neolife Medical Team

For years, hypertension was understood as a number: above 140/90 mmHg meant “disease”; below that threshold, “everything was fine.”

Today we know this approach is insufficient. The most recent evidence points to something more profound: elevated blood pressure is the late consequence of accelerated arterial aging—now recognized as vascular aging—which can be detected long before the blood pressure cuff shows abnormal values.

What truly matters is no longer just measuring blood pressure, but understanding what is happening inside the arteries during that silent phase that determines future risk, even when everything appears normal. This represents one of the most important evolutions of recent years: hypertension is no longer seen solely as a diagnosis, but as an opportunity for early detection. A paradigm shift that reshapes how we assess cardiovascular risk and opens the door to earlier, more precise intervention with a real capacity for long-term prevention.

Over the past decade, we have learned that:

• Vascular damage begins 5–10 years before blood pressure readings become elevated.
• Arterial stiffness predicts real cardiovascular risk more accurately than brachial blood pressure.
• Many individuals with “normal–high” blood pressure already show signs of arterial aging.

For this reason, the latest updates prioritize the assessment of vascular physiology rather than interpreting numbers alone.

Arterial stiffness: the first “surname” of hypertension

One of the parameters that has gained the most relevance in recent years is pulse wave velocity (PWV), an essential marker of arterial stiffness. Understanding it is simple if we imagine our arteries as household pipes: when they are new, flexible, and well maintained, they absorb pressure and allow smooth flow. Over time, as they become stiffer, each pressure wave travels faster and with greater force.

PWV measures exactly how fast the pressure wave travels along the aorta.

When this wave travels too quickly, the artery has lost elasticity. And this can occur years before blood pressure rises. In other words, a person may have “normal blood pressure” and yet already display the first surname of future hypertension: increased arterial stiffness, indicating premature vascular aging.

SphygmoCor: measuring what very few can

Assessing arterial stiffness cannot be done with a conventional blood pressure monitor. At Neolife, we use SphygmoCor, the international reference technology used in advanced cardiovascular research.

This highly validated system allows us to:

• Accurately measure PWV.
• Calculate central blood pressure, which is the pressure that truly loads the heart and brain.
• Determine whether a patient’s arterial stiffness is appropriate for their age or reflects accelerated vascular aging.

This technology, although widely validated, is still largely limited to centers with an advanced approach to vascular assessment. Its true value lies in its ability to detect alterations during the silent phase, when intervention is still both effective and highly personalized.

This is the foundation of true prevention—not merely reactive care.

RAAS and the renin/aldosterone ratio: the second surname of hypertension

In recent years—and particularly in the most recent updates—the renin/aldosterone ratio has gained greater importance, as it allows us to go beyond blood pressure values and understand the internal mechanism driving blood pressure elevation in each individual.

The RAAS (renin–angiotensin–aldosterone system) is the body’s mechanism for regulating blood pressure, salt balance, and fluid volume. It functions as an internal blood pressure thermostat: when the body perceives insufficient pressure or volume, it activates the system to raise it; when there is excess, it suppresses it.

• Renin is the initial signal, released when the body detects low pressure or volume.
• Renin triggers the formation of angiotensin, which constricts arteries and rapidly increases blood pressure.
• Angiotensin then stimulates the release of aldosterone, a hormone that promotes sodium and water retention, increasing circulating volume and sustaining elevated blood pressure.

By analyzing the renin/aldosterone ratio, we can identify which part of the system is altered—essentially determining the physiological mechanism pushing blood pressure upward in that specific individual. This is key to personalizing treatment and identifying the “second surname” of hypertension: whether there is excessive system activation, aldosterone predominance, or abnormally low renin levels.

This approach allows us to move away from the uniform “one-size-fits-all” strategy. While some profiles clearly benefit from ACE inhibitors or angiotensin II receptor blockers (ARBs), others respond better to calcium channel blockers, beta-blockers, aldosterone antagonists, or even targeted supplementation and lifestyle optimization strategies.

Lifestyle in 2026: interventions that truly rejuvenate the vasculature

New guidelines emphasize something we know well at Neolife: not all lifestyle recommendations impact arterial health in the same way. Certain interventions directly improve arterial stiffness and central blood pressure.

Resistance training combined with high-intensity intervals improves aortic elasticity more effectively than moderate exercise alone. Reducing visceral fat decreases hemodynamic load and improves central pressure.
Achieving deep, stable sleep—particularly restoring the normal “dipper” pattern—acts as a powerful nocturnal cardiovascular protector.
The dipper pattern refers to the natural nighttime reduction in blood pressure, typically around 10–20%. When this decline does not occur, cardiovascular risk increases significantly. It is assessed through 24-hour ambulatory blood pressure monitoring (ABPM), which tracks blood pressure behavior during sleep.

Importantly, these changes are not applied intuitively, but through a personalized approach: identifying the dominant mechanism in each individual and directing lifestyle interventions toward that specific target.

Because hypertension is not prevented with generic advice, but by optimizing arterial physiology through precise and measurable interventions.

The true antiaging approach: acting before disease appears

Traditional medicine diagnoses hypertension once blood pressure crosses a defined threshold. Longevity medicine prefers to intervene when physiology begins to deviate—before pathological numbers appear—helping the body return to its natural, physiological balance.

If a patient already shows a first surname (increased arterial stiffness), a second surname (altered RAAS), or even rising central blood pressure, we are facing an early but still manageable process. This is the window of opportunity to get ahead of arterial aging and prevent long-term complications.

That is the Neolife approach: anticipate, identify early changes, and act with precision to keep arterial health on its youngest possible trajectory.

BIBLIOGRAPHY

(1) Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071.

(2) McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, Christodorescu RM, Daskalopoulou SS, Ferro CJ, Gerdts E, Hanssen H, Harris J, Lauder L, McManus RJ, Molloy GJ, Rahimi K, Regitz-Zagrosek V, Rossi GP, Sandset EC, Scheenaerts B, Staessen JA, Uchmanowicz I, Volterrani M, Touyz RM; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024 Oct 7;45(38):3912-4018.

(3) Herzog MJ. Arterial stiffness and vascular aging: mechanisms, clinical implications, measurement and future perspectives. Signal Transduct Target Ther. 2025;10:23.

(4) Adler, G. K., Brown, J. M., Vaidya, A., Calhoun, D. A., Carey, R. M., Funder, J. W., Stowasser, M., & the Endocrine Society. (2025). Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. , ePub ahead of print.

(5) Manual MSD.

The combination of bioidentical estradiol and micronized progesterone has shown, according to scientific literature, no association with thrombotic events or an increased risk of breast cancer.

The warnings about hormone replacement therapy (HRT) date back to 2002, when the Women’s Health Initiative (WHI) study linked the combined therapy CEE + MPA (Conjugated Equine Estrogens + Medroxyprogesterone Acetate) to an increased risk of breast cancer and cardiovascular events.

Dr. Alfonso Galán – Neolife Medical Team

Women suffering from debilitating symptoms were kept away from an effective treatment due to unfounded fears, losing quality of life as well as bone and vascular protection.

In July 2025, the U.S. Food and Drug Administration (FDA) convened a panel of experts to reevaluate the evidence surrounding Hormone Replacement Therapy (HRT) in menopausal women. This marks a turning point in the institutional narrative that, for decades, has been dominated by fear, black box warnings, and a distorted perception of risk.

At Neolife, we welcome this step as an act of scientific and medical justice — but also as a reminder of the great harm that misinformation about HRT has caused. In this article, we analyze in depth the panel’s conclusions, the key studies discussed, and, above all, the fact that the formulations we use at Neolife (bioidentical estradiol and micronized progesterone) have shown no increase in cardiovascular or cancer risk.

What Was Said at the FDA Panel?

1. Removal of the most severe warnings (black box warnings) for certain forms of HRT.
2. Recognition of previously minimized benefits: cardiovascular protection, improved bone health, reduction of hot flashes, and enhanced mood—especially in women under 60 or within the first 10 years after menopause.
3. Lack of differentiation between formulations: one major criticism was the failure to distinguish between treatments using conjugated equine estrogens (CEE) and medroxyprogesterone (MPA), versus bioidentical options.

The Legacy of the WHI and Its Consequences

The warnings about HRT trace back to 2002, when the Women’s Health Initiative linked CEE + MPA to an increased risk of breast cancer and cardiovascular events. However, in the years since, it has become clear that:

• The observed risk does not apply to all formulations or all women.
• The late age of treatment initiation (average age in WHI: 63 years) distorted the outcomes.
• The study did not use bioidentical estrogens or micronized progesterone.

As a result, millions of women gave up a beneficial therapy based on fears that we now consider unfounded for many patients.

Current Evidence: What Does Science Say About Bioidentical HRT?

Studies such as E3N (France) have demonstrated that oral bioidentical estradiol combined with micronized progesterone does not increase breast cancer risk (RR: 0.9).

A meta-analysis (Scarabin, 2018) confirms that the safest combination is transdermal estradiol plus micronized progesterone, with no significant increase in thromboembolic risk.

Differences between formulations

The Neolife Approach: Evidence, Personalization, and Safety

At Neolife, we use HRT in a personalized and evidence-based manner, with:

• Bioidentical estradiol
• Micronized progesterone
• Regular clinical and laboratory monitoring

This combination has consistently shown no association with thrombotic events or increased breast cancer risk in the short- to medium-term scientific literature.

What Happens Next?

If the FDA is now willing to reconsider its most severe warnings based on current evidence, the next logical step would be to retract and acknowledge the harm caused over the past two decades.
Women with debilitating symptoms were denied an effective treatment due to misplaced fears, losing not only quality of life but also bone and vascular protection.

Medicine must have the courage to correct its course. Today, we know that well-prescribed, bioidentical, and personalized HRT is a powerful, effective, and safe tool for many women.

Conclusion

The FDA panel marks a shift in direction, but there is still a long road ahead — many physicians and patients remain to be educated. At Neolife, we have long applied an evidence-based approach, free from dogma and with safety as our top priority. It is time to rewrite the narrative of HRT — with science, prudence, and respect for women’s health.

BIBLIOGRAPHY

(1) Scarabin, P. Y. (2018). Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. Climacteric, 21(4), 341–345.

(2) Fournier, A. et al. (2008). Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. Journal of Clinical Oncology, 26(8), 1260–1268.
(E3N cohort, Francia)

(3) Manson, J. E. et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353–1368.

(4) The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 29(7), 767–794.

(5) FDA Expert Panel on Menopause and Hormone Replacement Therapy (2025). U.S. Food & Drug Administration Public Meeting Archive: July 17, 2025.